290 related articles for article (PubMed ID: 27720231)
1. The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.
Shafrir AL; Rice MS; Gupta M; Terry KL; Rosner BA; Tamimi RM; Hecht JL; Tworoger SS
Gynecol Oncol; 2016 Dec; 143(3):628-635. PubMed ID: 27720231
[TBL] [Abstract][Full Text] [Related]
2. Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study.
Hecht JL; Kotsopoulos J; Hankinson SE; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1624-30. PubMed ID: 19383883
[TBL] [Abstract][Full Text] [Related]
3. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
4. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.
Wentzensen N; Poole EM; Trabert B; White E; Arslan AA; Patel AV; Setiawan VW; Visvanathan K; Weiderpass E; Adami HO; Black A; Bernstein L; Brinton LA; Buring J; Butler LM; Chamosa S; Clendenen TV; Dossus L; Fortner R; Gapstur SM; Gaudet MM; Gram IT; Hartge P; Hoffman-Bolton J; Idahl A; Jones M; Kaaks R; Kirsh V; Koh WP; Lacey JV; Lee IM; Lundin E; Merritt MA; Onland-Moret NC; Peters U; Poynter JN; Rinaldi S; Robien K; Rohan T; Sandler DP; Schairer C; Schouten LJ; Sjöholm LK; Sieri S; Swerdlow A; Tjonneland A; Travis R; Trichopoulou A; van den Brandt PA; Wilkens L; Wolk A; Yang HP; Zeleniuch-Jacquotte A; Tworoger SS
J Clin Oncol; 2016 Aug; 34(24):2888-98. PubMed ID: 27325851
[TBL] [Abstract][Full Text] [Related]
5. Expression of gonadal steroid receptors in the ovaries of post-menopausal women with malignant or benign endometrial pathology: a pilot study.
Panoulis K; Christantoni E; Pliatsika P; Anagnostis P; Goulis DG; Kondi-Pafiti A; Armeni E; Augoulea A; Triantafyllou N; Creatsa M; Lambrinoudaki I
Gynecol Endocrinol; 2015; 31(8):613-7. PubMed ID: 26036714
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors.
Farinola MA; Gown AM; Judson K; Ronnett BM; Barry TS; Movahedi-Lankarani S; Vang R
Int J Gynecol Pathol; 2007 Oct; 26(4):375-82. PubMed ID: 17885486
[TBL] [Abstract][Full Text] [Related]
7. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q
Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin.
Kotsopoulos J; Terry KL; Poole EM; Rosner B; Murphy MA; Hecht JL; Crum CP; Missmer SA; Cramer DW; Tworoger SS
Int J Cancer; 2013 Aug; 133(3):730-9. PubMed ID: 23364849
[TBL] [Abstract][Full Text] [Related]
9. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.
Fujimura M; Hidaka T; Kataoka K; Yamakawa Y; Akada S; Teranishi A; Saito S
Am J Surg Pathol; 2001 May; 25(5):667-72. PubMed ID: 11342781
[TBL] [Abstract][Full Text] [Related]
10. Effects of pre- and postmenopausal use of exogenous hormones on receptor content in normal human breast tissue: a randomized study.
Hallberg G; Persson I; Naessén T; Magnusson C
Gynecol Endocrinol; 2008 Aug; 24(8):475-80. PubMed ID: 18850387
[TBL] [Abstract][Full Text] [Related]
11. The Association Between Talc Use and Ovarian Cancer: A Retrospective Case-Control Study in Two US States.
Cramer DW; Vitonis AF; Terry KL; Welch WR; Titus LJ
Epidemiology; 2016 May; 27(3):334-46. PubMed ID: 26689397
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
[TBL] [Abstract][Full Text] [Related]
13. Association between chronological change of reproductive factors and breast cancer risk defined by hormone receptor status: results from the Seoul Breast Cancer Study.
Chung S; Park SK; Sung H; Song N; Han W; Noh DY; Ahn SH; Yoo KY; Choi JY; Kang D
Breast Cancer Res Treat; 2013 Aug; 140(3):557-65. PubMed ID: 23901017
[TBL] [Abstract][Full Text] [Related]
14. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness.
Poole EM; Merritt MA; Jordan SJ; Yang HP; Hankinson SE; Park Y; Rosner B; Webb PM; Cramer DW; Wentzensen N; Terry KL; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):429-37. PubMed ID: 23307531
[TBL] [Abstract][Full Text] [Related]
15. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study.
Tung KH; Goodman MT; Wu AH; McDuffie K; Wilkens LR; Kolonel LN; Nomura AM; Terada KY; Carney ME; Sobin LH
Am J Epidemiol; 2003 Oct; 158(7):629-38. PubMed ID: 14507598
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of hormonal receptor status of malignant ovarian tumors.
Tkalia IG; Vorobyova LI; Svintsitsky VS; Nespryadko SV; Goncharuk IV; Lukyanova NY; Chekhun VF
Exp Oncol; 2014 Jun; 36(2):125-33. PubMed ID: 24980769
[TBL] [Abstract][Full Text] [Related]
17. Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study.
Ritte R; Tikk K; Lukanova A; Tjønneland A; Olsen A; Overvad K; Dossus L; Fournier A; Clavel-Chapelon F; Grote V; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Berrino F; Mattiello A; Tumino R; Sacerdote C; Quirós JR; Buckland G; Molina-Montes E; Chirlaque MD; Ardanaz E; Amiano P; Bueno-de-Mesquita HB; van Gils CH; Peeters PH; Wareham N; Khaw KT; Key TJ; Travis RC; Weiderpass E; Dumeaux V; Lund E; Sund M; Andersson A; Romieu I; Rinaldi S; Vineis P; Merritt MA; Riboli E; Kaaks R
BMC Cancer; 2013 Dec; 13():584. PubMed ID: 24321460
[TBL] [Abstract][Full Text] [Related]
18. Hormone replacement therapy and risk of epithelial ovarian cancer.
Purdie DM; Bain CJ; Siskind V; Russell P; Hacker NF; Ward BG; Quinn MA; Green AC
Br J Cancer; 1999 Oct; 81(3):559-63. PubMed ID: 10507786
[TBL] [Abstract][Full Text] [Related]
19. Reproductive characteristics in relation to ovarian cancer risk by histologic pathways.
Merritt MA; De Pari M; Vitonis AF; Titus LJ; Cramer DW; Terry KL
Hum Reprod; 2013 May; 28(5):1406-17. PubMed ID: 23315066
[TBL] [Abstract][Full Text] [Related]
20. Reproductive and hormonal factors, family history, and breast cancer according to the hormonal receptor status.
Rosato V; Bosetti C; Negri E; Talamini R; Dal Maso L; Malvezzi M; Falcini F; Montella M; La Vecchia C
Eur J Cancer Prev; 2014 Sep; 23(5):412-7. PubMed ID: 23817433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
